Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 6/20 | 0.54 |
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.54 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.53 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.53 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.53 |
| ▸ | FAAH | O00519 | 2/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.52 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.52 |
| ▸ | P2RY10 | O00398 | 1/20 | 0.51 |
| ▸ | GPR174 | Q9BXC1 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6338180 | 1.00 | LPAR1 (0.54) | LPAR1LPAR3ENPP2LPAR2S1PR1 | |
| SCHEMBL6348306 | 0.84 | EPHX2 (0.51) | LPAR1FAAHEPHX2CNR1CNR2 | |
| SCHEMBL6348309 | 0.84 | EPHX2 (0.51) | LPAR1FAAHEPHX2CNR1CNR2 | |
| SCHEMBL8508082 | 0.78 | P2RY10 (0.73) | LPAR1LPAR3ENPP2LPAR2PLA2G4A | |
| SCHEMBL6348463 | 0.78 | P2RY10 (0.73) | LPAR1LPAR3ENPP2LPAR2PLA2G4A | |
| SCHEMBL6336785 | 0.78 | P2RY10 (0.73) | LPAR1LPAR3ENPP2LPAR2PLA2G4A | |
| SCHEMBL6338286 | 0.78 | P2RY10 (0.73) | LPAR1LPAR3ENPP2LPAR2PLA2G4A | |
| SCHEMBL6337771 | 0.78 | P2RY10 (0.73) | LPAR1LPAR3ENPP2LPAR2PLA2G4A | |
| SCHEMBL6338834 | 0.78 | P2RY10 (0.73) | LPAR1LPAR3ENPP2LPAR2PLA2G4A | |
| SCHEMBL6345807 | 0.78 | P2RY10 (0.73) | LPAR1LPAR3ENPP2LPAR2PLA2G4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6911553-B1 | Osteoblast-specific mitogens and drugs containing such compounds | ROCHE DIAGNOSTICS GMBH (DE) | 2005-06-28 | — | — | US | disclosed |
| US-20050014723-A1 | Osteoblast-specific mitogens and drugs containing such compounds | ESSWEIN ANGELIKA (DE) | 2005-01-20 | — | — | US | disclosed |
| US-6197759-B1 | ADMINISTERING LYSOPHOSPHATIDYLIC ACID DERIVATIVE | ROCHE DIAGNOSTICS GMBH (DE) | 2001-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014723-A1 | Osteoblast-specific mitogens and drugs containing such compounds | LPAR1, LPAR2, LPAR4 | LPAR1 1/4885LPAR3 7/4885ENPP2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.